GNFTF Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Genfit SA's net margin of --. Genfit SA's return on equity of -- beat DBV Technologies SA's return on equity of -280.59%.

Genfit SA has a consensus price target of --, signalling downside risk potential of --. On the other hand DBV Technologies SA has an analysts' consensus of $40.16 which suggests that it could grow by 86.61%. Given that DBV Technologies SA has higher upside potential than Genfit SA, analysts believe DBV Technologies SA is more attractive than Genfit SA.

Genfit SA has a beta of 0.130, which suggesting that the stock is 86.956% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.978, suggesting its less volatile than the S&P 500 by 197.819%.

Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Genfit SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Genfit SA's net income of -- is lower than DBV Technologies SA's net income of -$33M. Notably, Genfit SA's price-to-earnings ratio is 49.25x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 9.90x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Ipsen SA has a net margin of -- compared to Genfit SA's net margin of --. Genfit SA's return on equity of -- beat Ipsen SA's return on equity of 11.08%.

Genfit SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Ipsen SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Genfit SA has higher upside potential than Ipsen SA, analysts believe Genfit SA is more attractive than Ipsen SA.

Genfit SA has a beta of 0.130, which suggesting that the stock is 86.956% less volatile than S&P 500. In comparison Ipsen SA has a beta of 0.499, suggesting its less volatile than the S&P 500 by 50.123%.

Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ipsen SA offers a yield of 0.83% to investors and pays a quarterly dividend of $0.40 per share. Genfit SA pays -- of its earnings as a dividend. Ipsen SA pays out 22.95% of its earnings as a dividend. Ipsen SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genfit SA quarterly revenues are --, which are smaller than Ipsen SA quarterly revenues of --. Genfit SA's net income of -- is lower than Ipsen SA's net income of --. Notably, Genfit SA's price-to-earnings ratio is 49.25x while Ipsen SA's PE ratio is 32.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 9.90x versus 3.83x for Ipsen SA. Usually stocks with elevated PS ratios are considered overvalued.

Nicox SA has a net margin of -- compared to Genfit SA's net margin of --. Genfit SA's return on equity of -- beat Nicox SA's return on equity of -43.13%.

Genfit SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Nicox SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Genfit SA has higher upside potential than Nicox SA, analysts believe Genfit SA is more attractive than Nicox SA.

Genfit SA has a beta of 0.130, which suggesting that the stock is 86.956% less volatile than S&P 500. In comparison Nicox SA has a beta of -0.043, suggesting its less volatile than the S&P 500 by 104.266%.

Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nicox SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. Nicox SA pays out -- of its earnings as a dividend.

Genfit SA quarterly revenues are --, which are smaller than Nicox SA quarterly revenues of --. Genfit SA's net income of -- is lower than Nicox SA's net income of --. Notably, Genfit SA's price-to-earnings ratio is 49.25x while Nicox SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 9.90x versus 5.89x for Nicox SA. Usually stocks with elevated PS ratios are considered overvalued.

Transgene SA has a net margin of -- compared to Genfit SA's net margin of --. Genfit SA's return on equity of -- beat Transgene SA's return on equity of -182.92%.

Genfit SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Transgene SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Genfit SA has higher upside potential than Transgene SA, analysts believe Genfit SA is more attractive than Transgene SA.

Genfit SA has a beta of 0.130, which suggesting that the stock is 86.956% less volatile than S&P 500. In comparison Transgene SA has a beta of 42.864, suggesting its more volatile than the S&P 500 by 4186.443%.

Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Transgene SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. Transgene SA pays out -- of its earnings as a dividend.

Genfit SA quarterly revenues are --, which are smaller than Transgene SA quarterly revenues of $105.2K. Genfit SA's net income of -- is lower than Transgene SA's net income of --. Notably, Genfit SA's price-to-earnings ratio is 49.25x while Transgene SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 9.90x versus 1,122.44x for Transgene SA. Usually stocks with elevated PS ratios are considered overvalued.